MUST READ: The Biden Administration just solved every problem in our economy and society with a bold new action plan – Step 1. reform drug pricing Step 2. See step 1. This can’t fail…
read full article ›Join us in celebrating Roger and all other named at the PharmaVoice 100 Celebration today!
read full article ›The NHS announced an inspiring new population health agreement today, making Novartis’ inclisiran available to 300,000+ patients with high cholesterol and a history of heart disease. This arrangement highlights the urgent need to apply alternative contracting solutions to ensure rapid patient access to innovative medicines- at scale.
read full article ›Some not so subtle points in the pipeline report from OptumRx: We’re watching... 1) orphan drugs carefully; and 2) how we can take advantage of even not-so-obvious ways of making them compete.
read full article ›ICER re-analyzed its original results on HAE which were based on trial results using real-world data from Aetion. Results: data showed significantly fewer baseline attacks meaning prophylactic therapies, per ICER, prevent fewer attacks than originally estimated…and that means the drugs’ economic value is lower.
read full article ›As a PBM, IngenioRx highlights their approach and the value of integrated management in their 2020 Trend Report and Specialty Supplement.
read full article ›Impossible to exclude life-saving orphan drugs from formularies? Not anymore. ESI says “no” to Pfizer’s and Takeda’s Gaucher disease agents in favor of Sanofi-Genzyme’s.
read full article ›How long until we see typical generic substitution and generic dispensing rates in the insulin glargine market?
read full article ›